No CrossRef data available.
Article contents
Frecuencia de la apolipoproteína E-ɛ4, en la esquizofrenia de déficit
Published online by Cambridge University Press: 12 May 2020
Resumen
Se ha encontrado que el genotipo de la apolipoproteína E (ApoE) afecta a la expresión de varios trastornos neuropsiquiátricos. Determinamos las frecuencias del genotipo de la ApoE y su relación con los síntomas negativos primarios en 61 pacientes esquizofrénicos sin déficit y 45 con déficit, y los comparamos con 98 sujetos de control. No se observaron diferencias cuando se compararon las frecuencias del genotipo o de los alelos entre los tres grupos. Nuestros datos no apoyan la existencia de un papel para la ApoE en la expresión fenotípica de la esquizofrenia.
- Type
- Artículo original
- Information
- Copyright
- Copyright © European Psychiatric Association 2000
References
Bibliografía
Amador, XF, Kirkpatrick, B, Carpenter, WT, Yale, SA, Marcinko, L.The long term stability of the definir syndrome. Schizophr Res 1996; 18: 116.CrossRefGoogle Scholar
American Psychiatry Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd edition. Washington, DC: American Psychiatric Press; 1987.Google Scholar
Andreasen, NC, Olsen, SA, Dennert, JW. Ventricular enlargement in schizophrenia: relationship to positive and negative symptoms. Am J Psychiatry 1982; 139; 297–302.Google ScholarPubMed
Arendt, T, Schindler, C, Brükner, MK, Eschrich, K, Bigl, V, Zedlick, D, et al. Plástic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apo-lipoprotein £4 alíele. J Neurosci 1997; 17: 516–29.CrossRefGoogle Scholar
Bickeboller, H, Campion, D, Brice, A, Amouyel, P, Hannequin, D, Didierjean, O.et al. Apolipoprotein E and Alzheimer disease: genotype specific risks by age and sex. Am J Hum Genet 1996; 60: 439–46.Google Scholar
Carpenter, WT, Buchanan, RW, Kirkpatrick, B, Tamminga, C, Wood, F.Strong inference, theory testing, and the neuroanatomy of schizophrenia. Arch Gen Psychiatry 1993; 50: 825–31.CrossRefGoogle ScholarPubMed
Corder, EH, Saunders, AM, Strittmatter, WJ, Schmechel, DE, Gaskell, PC, Small, GW, et al. Gene dose of apolipoprotein E type 4 alíele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921–23.CrossRefGoogle Scholar
Hixson, JE, Vernier, DTRestriction isotyping of human ApoE by gene amplification and cleavage with Hhal. Lipid Res 1990: 31: 545–8.Google Scholar
Jonsson, E, Lannfelt, L, Engvall, B, Sedvalla, G.Lack of association between schizophrenia and the apolipoprotein E epsilon 4 alíele. Eur Arch Psychiatry Clin Neurosci 1996; 246: 182–4.CrossRefGoogle Scholar
Joober, R, Rouleau, G, Fon, E, Lal, S, Palmour, R, Bloom, D, et al. Apolipoprotein E genotype in schizophrenia. Am J Med Genet 1996; 67: 235.CrossRefGoogle Scholar
Kay, SR, Fiszbein, A, Opler, LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–76.CrossRefGoogle Scholar
Kirkpatrick, B, Buchanan, RW, McKenney, PD, Alphs, LD, Carpenter, WT. The schedule for the déficit syndrome: an instrument for research in schizophrenia. Psychiatry Res 1989; 30: 119–23.CrossRefGoogle Scholar
Lan, TH, Hong, CJ, Chen, JY, Sim, CB. Apolipoprotein E- epsilon 4 frequency in patients with schizophrenia. Biol Psychiatry 1997; 42: 225–7.Google ScholarPubMed
Marneros, A, Deister, A, Rhode, A.Validity of the negative/positive dichotomy for schizophrenic disorders under long-term conditions. Schizophr Res 1992; 7: 117–23.CrossRefGoogle ScholarPubMed
Nathan, BP, Bellosta, S, Sanan, A, Weisgraber, KH, Mahley, RW, Pitas, RE. Differential effects of apolipoprotein ε1, and ε1, on neuronal growth in vitro. Science 1997; 264: 850–2.CrossRefGoogle Scholar
Overall, JE, Gorham, DE. The brief psychiatric rating scale. Psychol Rep 1961; 10: 799–812.CrossRefGoogle Scholar
Pearlson, GD, Garbacz, DJ, Breakey Ahn, HS, Depaulo, JR. Lateral ventricular enlargement associated with persistent un-employment and negative symptoms in both schizophrenia and bipolar disorder. Psychiatry Res 1984; 12: 1–9.CrossRefGoogle Scholar
Pickar, D, Malhotra, AK, Rooney, W, Breier, A, Goldman, D.Apolipoprotein E epsilon 4 and clinical phenotype in schizophrenia. Lancet 1997; 350: 930–1.CrossRefGoogle Scholar
Powchik, P, Friedman, J, Haroutunian, V, Greenberg, D, Altstein, L, Purohit, D, et al. Apolipoprotein £. in schizophrenia: study of one hundred sixteen cases with concomitant neuropathologies examination. Biol Psychiatry 1997; 42: 296–8.CrossRefGoogle Scholar
Ribeyre, JM, Dollfus, D, Lesieur, P, Ménard, JF, Petit, M.Instrument d'évaluation du syndrome déficitaire de la schizophrénie. Encephale 1994; 20: 413–9.Google Scholar
Soininen, HS, Riekkinen, PJ. Apolipoprotein E, memory and Alzheimer’s disease. Trends Neurosci 1996; 19: 224–8.CrossRefGoogle ScholarPubMed
Strittmatter, WJ, Saunders, AM, Schmechel, D, Pericak-Vance, M, Enghild, J, Salvesen, GS, et al. Apolipoprotein E: high avidity binding to amyloid and increased frequency of type 4 alíele in late onset familial Alzheimer's disease. Proc Nati Acad Sci USA 1993; 90: 1977–81.CrossRefGoogle Scholar
Thibaut, F, Ribeyre, JM, Dourmap, N, Ménard, JF, Dollfus, S, Petit, M.Plasma 3-methoxy-4-hydroxyphenylglycol and homovanillic acid measurements in déficit and non-deficit forms of schizophrenia. Biol Psychiatry 1988; 43: 24–30.CrossRefGoogle Scholar
Zhu, S, Nothen, MM, Uhlhass, S, Rietschel, M, Koerner, J, Lanczik, M, et al. Apolipoprotein E genotype distribution in schizophrenia. Psychiatr Genet 1996; 6:75–9.CrossRefGoogle Scholar